Compare UBSI & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBSI | LGND |
|---|---|---|
| Founded | 1982 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.0B |
| IPO Year | 1994 | 1997 |
| Metric | UBSI | LGND |
|---|---|---|
| Price | $48.59 | $316.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $51.67 | ★ $361.27 |
| AVG Volume (30 Days) | ★ 822.4K | 185.1K |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | ★ 2.77 | 0.31 |
| Revenue | ★ $311,957,000.00 | $141,102,000.00 |
| Revenue This Year | $4.32 | $8.82 |
| Revenue Next Year | $5.54 | $31.67 |
| P/E Ratio | ★ $17.57 | $1,019.68 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $34.68 | $175.89 |
| 52 Week High | $50.47 | $326.63 |
| Indicator | UBSI | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 55.75 |
| Support Level | $47.69 | $277.97 |
| Resistance Level | $49.62 | $319.83 |
| Average True Range (ATR) | 1.01 | 11.45 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 49.58 | 67.94 |
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which offers a full range-of-products and services through various delivery channels. Included among the banking products and services offered are the acceptance of deposits in checking, savings, time, and money market accounts; the making and servicing of personal, credit card, commercial, and floor plan loans; and the making of construction and real estate loans, as well as the origination and sale of residential mortgages in the secondary market. Also offered are trust and brokerage services, safe deposit boxes, and wire transfers.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.